Annual report pursuant to Section 13 and 15(d)

Nature of Operations and Summary of Significant Accounting Policies (Tables)

v3.24.0.1
Nature of Operations and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Schedule of Franchisor Disclosure
The following table summarizes the number of clinics in operation under franchise agreements and as company-owned or managed for the years ended December 31, 2023 and 2022:
Year Ended December 31,
Franchised clinics: 2023 2022
Clinics open at beginning of period 712  610 
Opened during the period 104  121 
Acquired during the period —  2 
Sold during the period (3) (16)
Closed during the period (13) (5)
Clinics in operation at the end of the period 800  712 
Year Ended December 31,
Company-owned or managed clinics: 2023 2022
Clinics open at beginning of period 126  96 
Opened during the period 10  16 
Acquired during the period 3  16 
Sold during the period —  (2)
Closed during the period (4) — 
Clinics in operation at the end of the period 135  126 
Total clinics in operation at the end of the period 935  838 
Clinic licenses sold but not yet developed 132  197 
Executed letters of intent for future clinic licenses 40  38 
Schedule of Earnings per Common Share
Year Ended December 31,
2023 2022
Net (loss) income $ (9,752,197) $ 626,705 
Weighted average common shares outstanding - basic 14,688,115  14,488,314 
Effect of dilutive securities:
Unvested restricted stock and stock options 247,102  379,779 
Weighted average common shares outstanding - diluted 14,935,217  14,868,093 
Basic (loss) earnings per share $ (0.66) $ 0.04 
Diluted (loss) earnings per share $ (0.65) $ 0.04 
Potentially dilutive securities excluded from the calculation of diluted net (loss) income per common share as the effect would be anti-dilutive were as follows:
Year Ended December 31,
2023 2022
Unvested restricted stock —  — 
Stock options 89,152  89,152